• Explore /
  • Poster
  • / Phase 2 of trametinib plus radioiodine in <em>RAS-</em>mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).

Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).

Abstract Poster

Authors

null

Bharat Burman

Memorial Sloan Kettering Cancer Center, New York, NY

Bharat Burman , R. Michael Tuttle , Ravinder K Grewal , Eric Jeffrey Sherman , Shrujal S. Baxi , Laura Boucai , Mona Sabra , Stephanie Fish , Keith S. Pentlow , Sofia Haque , Irina Ostrovnaya , Ronald A Ghossein , Helen X. Chen , John Humm , Michael Anthony Carducci , Steven M. Larson , David G. Pfister , James A Fagin , Alan Loh Ho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT02152995

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6089)

DOI

10.1200/JCO.2022.40.16_suppl.6089

Abstract #

6089

Poster Bd #

80

Abstract Disclosures

Similar Posters

First Author: Gregory J. Riely

First Author: Daisuke Kotani

First Author: Matthew H. Taylor

First Author: Shirish M. Gadgeel